Mammary Cell News 11.30 August 8, 2019 | |
| |
TOP STORYScientists identified four functional CCCTC-binding factor (CTCF)-binding elements (CBEs) and demonstrated the role of one of them in inducing chromatin conformation changes in favor of activation of PREX1, a key estrogen receptor α (ERα) target gene in breast cancer. Indeed, high PREX1 expression was a bona-fide marker of ERα-dependency in cell lines, and was associated with good outcome after anti-hormonal treatment. [Nucleic Acids Res] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Investigators investigated the cancer stem cell (CSC)-specific function of HDAC1 and HDAC7 mechanistically by using a stem-like breast cancer (BrCa) cell model BPLER and matched non-stem tumor cell-like HMLER, along with conventional BrCa cell lines with different CSC enrichment levels. [Oncogene] Full Article According to the prioritization of variation in ER-negative-associated lncRNAs, researchers identified and investigated the role of LINC00511 in breast cancer. They determined that high LINC00511 expression was an unfavorable prognostic factor for patients with breast cancer. [Cell Death Dis] Full Article The authors found that pristimerin reduced the viability of breast cancer cells in vitro and the growth of xenografts in vivo, and these reductions were accompanied by thioredoxin-1 inhibition and ASK1 and JNK activation. [Cell Death Discov] Full Article Niclosamide, an FDA approved anthelminthic drug, was evaluated for its anti-breast cancer activity and its ability to inhibit adipocytes induced epithelial-to-mesenchymal transition. Niclosamide potently inhibited proliferation, migration and invasion at low concentration and induced significant apoptosis at high concentrations in human breast cancer cell lines MDA-MB-468 and MCF-7. [Sci Rep] Full Article Investigators performed molecular profiling using targeted next-generation sequencing on 94 HER2-positive luminal B breast cancers to identify its molecular characteristics. A total of 134 somatic nonsynonymous mutations, including 131 nonsynonymous single nucleotide variants and three coding insertions/deletions were identified in 30 genes of 75 samples. [Sci Rep] Full Article An Antisense Transcript Mediates MALAT1 Response in Human Breast Cancer Using a collection of breast cancer cells and in vitro and in vivo migration assays, researchers characterized the dynamics of expression and demonstrated that TALAM1 regulated and synergized with MALAT1 during tumorigenesis. Down-regulation of TALAM1 was shown to greatly impact on the capacity of breast cancer cells to migrate in vitro or to populate the lungs of immunocompromised mice. [BMC Cancer] Full Article The expression of miR-20a-5p in the primary murine bone marrow macrophages, MCF-10A, MCF-7, and MDA-MB-231 cell lines, as well as the cell-derived exosomes were assessed by qRT-PCR. Transwell assays were used to evaluate the effects of miR20a-5p on tumor cell migration and invasion. [Cancer Med] Full Article Fluorescence-Based Discrimination of Breast Cancer Cells by Direct Exposure to 5-Aminolevulinic Acid Fluorescence intensity was measured in the human breast cancer cell lines MCF7 and MDA-MB-231 and breast epithelial cell line MCF10A by confocal microscopy and flow cytometry. After 5-aminolevulinic acid exposure for two hours, protoporphyrin IX-FI in MCF7 and MDA-MB-231 cells significantly increased with marked cell-to-cell variability, whereas that in MCF10A cells increased moderately. [Cancer Med] Full Article miR-16-5p Inhibits Breast Cancer by Reducing AKT3 to Restrain NF-kB Pathway The clinical data was analyzed with qRT-PCR. CCK8, EdU and Tranwell was performed to explore the function of miR-16-5p in cell migration and proliferation of breast cancer cells. Dual-luciferase reporter assay, immunohistochemistry and Western blotting were carried out to explore the relation between miR-16-5p and AKT3. [Biosci Rep] Full Article Scientists investigated the expression of zinc finger and BTB domain containing 7A (ZBTB7A) in tissue samples of clinical breast cancer patients, MDA-MB-231, MCF-7 and MCF-10A cells. They over-expressed the ZBTB7A in MCF-7 cells and silenced the ZBTB7A in MDA-MB-231 cells using lentivirus transfection technology respectively, and verified the effect of ZBTB7A on migration and invasion of breast cancer cell lines through in vitro cell function experiments, such as wound healing assay, migration and invasion assay, qRT-PCR and Western blot. [J Biochem] Abstract TRAF6 Maintains Mammary Stem Cells and Promotes Pregnancy-Induced Mammary Epithelial Cell Expansion Researchers showed that tumor necrosis factor receptor-associated factor 6 (TRAF6) was crucial for both mammary stem cell maintenance and pregnancy-induced epithelial cell expansion. TRAF6 deficiency impaired phosphoinositide 3-kinase (PI3K)/AKT and canonical NF-κB pathways, whereas noncanonical NF-κB signaling remained functional. [Commun Biol] Full Article Subscribe to one of our other 19 science newsletters such as Prostate Cell News & ESC & iPSC News. | |
| |
REVIEWSPregnancy and Breast Cancer: Pathways to Understand Risk and Prevention The authors discuss mechanisms that react to pregnancy signals, and they delineate the nuances of pregnancy-associated dynamism that contribute towards either breast cancer development or prevention. Further definition of the molecular basis of parity and breast cancer risk may allow the elaboration of tools to predict and survey those who are at risk of breast cancer development. [Trends Mol Med] Full Article 3D Printing Breast Tissue Models: A Review of Past Work and Directions for Future Work Investigators review the work that has been undertaken in hopes of generating the recognized in-demand replacement breast tissue using different types of bio-printing. They then offer suggestions for future work needed to advance this field for both in vitro and in vivo applications. [Micromachines] Full Article Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
INDUSTRY NEWSAthenex, Inc. announced topline data showing that oral paclitaxel and encequidar met the primary efficacy endpoint with statistically significant improvement over IV paclitaxel in a Phase III pivotal study in metastatic breast cancer. [Athenex, Inc.] Press Release SELLAS Life Sciences Group, Inc. announced completion of enrollment in a Phase II randomized investigator-sponsored trial of NPS in combination with granulocyte-macrophage colony-stimulating factor in women with DCIS of the breast who are HLA-A2+ or A3+ positive, express HER2 at IHC 1+, 2+, or 3+ levels, and are pre- or post-menopausal. [SELLAS Life Sciences Group, Inc.] Press Release CollPlant Is Developing 3D-Bioprinted Implants for Regeneration of Breast Tissue CollPlant announced that it is developing 3D bioprinted implants for regeneration of breast tissue and has successfully produced first prototypes. The implants will be comprised of CollPlant’s proprietary type I recombinant human collagen and additional materials. Loaded with fat cells taken from the patient, these implants are intended to promote breast tissue regeneration. [CollPlant] Press Release | |
| |
POLICY NEWSMexican Science Suffers under Debilitating Budget Cuts Austerity measures recently enacted by Mexico’s president are pushing the country’s scientific efforts — chronically underfunded for years — to a breaking point, according to researchers. [Nature News] Editorial Novartis CEO: ‘We Tried to Do the Right Things’ in FDA Data Scandal Novartis CEO Vas Narasimhan defended his company’s decision to wait three months to tell authorities about falsified data submitted to the FDA, saying the company “tried to do the right things” in the process. He also said Novartiswas now “in the process of exiting” a small number of scientists at AveXis, Novartis’s gene therapy business, who were “involved in these data inaccuracies.” [STAT News] Editorial With Its CRISPR Revolution, China Becomes a World Leader in Genome Editing In 2012, the year researchers transformed a bacterial immune system into the fast and versatile tool for genome engineering, scientific publications mentioning CRISPR totaled 127. Since then there have been more than 14,000. Although the United States has had the most CRISPR publications-and continues to have the most cited papers—China is now a close second and is pouring money into CRISPR’s uses. [ScienceInside] Editorial
| |
EVENTSNEW Tumor Heterogeneity, Plasticity, and Therapy Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Fellow – T-Cell Immunotherapy in Cancers (Memorial Sloan Kettering Cancer Center) Scientific Communications Coordinator (STEMCELL Technologies Inc.) Postdoctoral Fellow – Breast Cancer (Monash University) Postdoctoral Fellow – Breast Cancer Research (Institute of Cancer Research) Research Lab Specialist – Tumor Microenvironment & Cell Behavior (University of Southern California) Postdoctoral Fellow – Cancer Drug Response Research (University of Texas at Austin) Canada Research Chair – Precision and Molecular Oncology (University of Calgary) Postdoctoral Associate – Immune Responses (The Jackson Laboratory) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|